长药控股(300391) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥545,403,773.14, a decrease of 30.53% compared to ¥785,147,049.48 in the same period last year[3] - Net profit attributable to shareholders was ¥14,645,911.14, down 75.35% from ¥59,407,361.17 year-on-year[3] - Total operating revenue for Q1 2022 was ¥545,403,773.14, a decrease of 30.6% compared to ¥785,147,049.48 in Q1 2021[16] - Net profit for Q1 2022 was ¥50,233,749.76, a decline of 52.8% from ¥106,260,897.63 in Q1 2021[17] - The net profit attributable to the parent company for Q1 2022 was ¥14,645,911.14, down 75.4% from ¥59,407,361.17 in Q1 2021[17] - The company reported a total comprehensive income of ¥50,190,853.23 for Q1 2022, down from ¥106,268,532.66 in the same period last year[17] Cash Flow - The net cash flow from operating activities was -¥41,839,544.89, a decline of 15.98% compared to -¥36,074,307.49 in the previous year[3] - Total cash inflow from operating activities was 496,174,234.37 CNY, down 36.0% from 774,178,788.15 CNY in the previous period[19] - Cash outflow from operating activities totaled 538,013,779.26 CNY, a decrease of 33.5% from 810,253,095.64 CNY in the previous period[19] - The net cash flow from investing activities was -58,158,351.82 CNY, worsening from -21,671,475.69 CNY in the previous period[20] - Cash inflow from financing activities was 451,762,000.00 CNY, an increase of 130.5% compared to 195,697,783.47 CNY in the previous period[20] - The net cash flow from financing activities improved to 194,088,746.52 CNY, compared to 8,179,398.42 CNY in the previous period[20] - The ending balance of cash and cash equivalents was 176,334,344.55 CNY, significantly up from 57,385,275.97 CNY in the previous period[20] - Cash received from the acquisition of loans was 408,012,000.00 CNY, compared to 169,980,000.00 CNY in the previous period, reflecting increased borrowing[20] - Cash paid for debt repayment was 245,753,032.67 CNY, an increase from 179,917,561.10 CNY in the previous period[20] Assets and Liabilities - Total assets increased by 3.81% to ¥4,375,196,841.05 from ¥4,214,473,787.82 at the end of the previous year[3] - Total liabilities as of Q1 2022 amounted to ¥2,715,869,616.76, an increase from ¥2,605,178,650.74 in the previous year[14] - Total equity attributable to shareholders of the parent company was ¥840,726,954.19, up from ¥826,282,705.59 in Q1 2021[14] - The company reported a total of 2,251,440,637.09 in current assets, up from 2,058,953,930.43, which is an increase of about 9.3%[13] - The company’s total current liabilities were ¥2,162,228,607.80, slightly up from ¥2,109,917,350.56 in Q1 2021[14] Shareholder Information - The total number of common shareholders at the end of the reporting period is 13,980[9] - The largest shareholder, Changxing Shengshi Fenghua Business Co., Ltd., holds 18.81% of shares, totaling 65,897,500 shares[9] Operational Metrics - The weighted average return on equity decreased to 1.76% from 7.37% year-on-year, a drop of 5.61%[3] - Research and development expenses for Q1 2022 were ¥8,157,597.25, a decrease from ¥10,940,213.27 in Q1 2021[16] - Total operating costs for Q1 2022 were ¥482,568,751.14, down 29.4% from ¥683,016,461.70 in the same period last year[16] - Basic and diluted earnings per share for Q1 2022 were both ¥0.0418, a decrease from ¥0.1696 in Q1 2021[18] Inventory and Receivables - Accounts receivable rose to ¥1,433,465,607.14 from ¥1,377,957,524.35, indicating an increase of about 4.0%[12] - Inventory decreased to ¥159,065,948.60 from ¥195,347,478.13, showing a decline of approximately 18.5%[13] Product Development and Mergers - The company did not report any new product developments or market expansion strategies during this quarter[3] - The company has not disclosed any new product or technology developments in the current report[10] - There are no significant mergers or acquisitions reported during the period[10] Audit Information - The company did not undergo an audit for the first quarter report[21]